TY - JOUR
T1 - Menopause—Biology, consequences, supportive care, and therapeutic options
AU - Pinkerton, Jo Ann
AU - Santoro, Nanette
AU - Simoncini, Tommaso
A2 - Davis, Susan R.
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/9/14
Y1 - 2023/9/14
N2 - Menopause is the cessation of ovarian function, with loss of reproductive hormone production and irreversible loss of fertility. It is a natural part of reproductive aging. The physiology of the menopause is complex and incompletely understood. Globally, menopause occurs around the age of 49 years, with geographic and ethnic variation. The hormonal changes of the menopause transition may result in both symptoms and long-term systemic effects, predominantly adverse effects on cardiometabolic and musculoskeletal health. The most effective treatment for bothersome menopausal symptoms is evidence-based, menopausal hormone therapy (MHT), which reduces bone loss and may have cardiometabolic benefits. Evidence-based non-hormonal interventions are also available for symptom relief. Treatment should be individualized with shared decision-making. Most MHT regimens are not regulator approved for perimenopausal women. Studies that include perimenopausal women are needed to determine the efficacy and safety of treatment options. Further research is crucial to improve menopause care, along with research to guide policy and clinical practice.
AB - Menopause is the cessation of ovarian function, with loss of reproductive hormone production and irreversible loss of fertility. It is a natural part of reproductive aging. The physiology of the menopause is complex and incompletely understood. Globally, menopause occurs around the age of 49 years, with geographic and ethnic variation. The hormonal changes of the menopause transition may result in both symptoms and long-term systemic effects, predominantly adverse effects on cardiometabolic and musculoskeletal health. The most effective treatment for bothersome menopausal symptoms is evidence-based, menopausal hormone therapy (MHT), which reduces bone loss and may have cardiometabolic benefits. Evidence-based non-hormonal interventions are also available for symptom relief. Treatment should be individualized with shared decision-making. Most MHT regimens are not regulator approved for perimenopausal women. Studies that include perimenopausal women are needed to determine the efficacy and safety of treatment options. Further research is crucial to improve menopause care, along with research to guide policy and clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85170231874&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2023.08.016
DO - 10.1016/j.cell.2023.08.016
M3 - Review Article
C2 - 37678251
AN - SCOPUS:85170231874
SN - 0092-8674
VL - 186
SP - 4038
EP - 4058
JO - Cell
JF - Cell
IS - 19
ER -